Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary adenocarcinoma of the rectum that begins within 15cm of the anal verge as determined by sigmoidoscopy or colonoscopy~* Clinical T3 or T4 tumors as determined by endoscopic ultrasound and/or rectal MRI~* ECOG performance status of 0-2~* 18 years of age or older~* Creatinine of \< 2.0~* Adequate hepatic function~* Adequate hematopoietic function~* Use of effective means of contraception in subjects of child-bearing potential~Exclusion Criteria:~* Evidence of metastatic disease as determined by chest/abdominal/pelvic CT or physical exam~* Prior chemotherapy or radiation therapy for treatment of colorectal cancer~* Prior treatment with 5-FU~* Prior treatment with a tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor~* Patients must not be receiving any other investigational agent~* Prior malignancy within the last 5 years except for completely excised skin cancer, in situ cervical cancer~* Warfarin anticoagulation~* Co-existent malignant disease~* Current or recent participation in a clinical trial (within 4 weeks from the first day of treatment)~* Pregnancy~* Blood pressure of \>150/100 mmHg~* Unstable angina~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction within 6 months~* History of stroke within 6 months~* Clinically significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastases~* Major surgical procedure, open biopsy, or significant trauma injury within 28 days prior to day 0, anticipation of need for major surgical procedure during the course of the study~* Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to day 0~* Pregnant or lactating~* Urine protein:creatinine ratio \> or equal to one at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0\]~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy and radiation (Type: EXPERIMENTAL): Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).